

# A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

NCT06921850

---

|                   |                   |
|-------------------|-------------------|
| <b>Status</b>     | RECRUITING        |
| <b>Phase</b>      | Phase 3           |
| <b>Sponsor</b>    | UCB Biopharma SRL |
| <b>Enrollment</b> | 40 participants   |

## Key Eligibility Criteria

---

### Inclusion (6)

- Study participant must be 12 to <18 years of age at the time of informed consent/assent, at Tanner stage 2 or more, for the first 8 participants only, followed by also including participants e9 to <18 years of age at Tanner stage 2 or more.
  - Study participant must have a diagnosis of HS for at least 6 months prior to the Baseline Visit.
  - Study participant must have moderate to severe HS, defined as a total of e5 inflammatory lesions (ie, the sum of abscesses and inflammatory nodules), as assessed at both the Screening and Baseline Visits.
  - Study participant must have HS lesions present in at least 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or III, as assessed at both the Screening and Baseline Visits.
  - Study participant must have had a history of inadequate response to a course of a systemic antibiotic for treatment of HS
- ... and 1 more (see full listing online)

### Exclusion (10)

- Study participant has a draining tunnel count of >20 at either the Screening or Baseline Visits.
  - Study participant has experienced primary failure (no response within 12 weeks) to 1 or more IL 17 biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR primary failure to more than 1 biologic response modifier other than an IL-17 biologic response modifier.
  - Study participant has previously participated in this study or has received previous therapy with bimekizumab.
  - Study participant has a history of IBD or symptoms suggestive of IBD.
  - History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated
- ... and 5 more (see full listing online)

## Locations (18 total)

---

Hs0006 50175, Phoenix, Arizona, United States  
Hs0006 50708, Roseville, California, United States  
Hs0006 50684, Sacramento, California, United States  
... and 15 more locations

---

<https://clinicaltrials.gov/study/NCT06921850>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.